The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study

• Published in: EClinicalMedicine Vol. 28; p. 100570
• Main Authors: Calligaro, Gregory L., Lalla, Usha, Audley, Gordon, Gina, Phindile, Miller, Malcolm G., Mendelson, Marc, Dlamini, Sipho, Wasserman, Sean, Meintjes, Graeme, Peter, Jonathan, Levin, Dion, Dave, Joel A., Ntusi, Ntobeko, Meier, Stuart, Little, Francesca, Moodley, Desiree L., Louw, Elizabeth H., Nortje, Andre, Parker, Arifa, Taljaard, Jantjie J., Allwood, Brian W., Dheda, Keertan, Koegelenberg, Coenraad F.N.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.11.2020; Elsevier
• Subjects: COVID-19; High flow nasal oxygen; Internal Medicine; Pneumonia; Research Paper; Ventilation; COVID-19; Ventilation; High flow nasal oxygen; Pneumonia
• ISSN: 2589-5370; 2589-5370
• DOI: 10.1016/j.eclinm.2020.100570

The utility of heated and humidified high-flow nasal oxygen (HFNO) for severe COVID-19-related hypoxaemic respiratory failure (HRF), particularly in settings with limited access to intensive care unit (ICU) resources, remains unclear, and predictors of outcome have been poorly studied. We included consecutive patients with COVID-19-related HRF treated with HFNO at two tertiary hospitals in Cape Town, South Africa. The primary outcome was the proportion of patients who were successfully weaned from HFNO, whilst failure comprised intubation or death on HFNO. The median (IQR) arterial oxygen partial pressure to fraction inspired oxygen ratio (PaO2/FiO2) was 68 (54–92) in 293 enroled patients. Of these, 137/293 (47%) of patients [PaO2/FiO2 76 (63–93)] were successfully weaned from HFNO. The median duration of HFNO was 6 (3–9) in those successfully treated versus 2 (1–5) days in those who failed (p<0.001). A higher ratio of oxygen saturation/FiO2 to respiratory rate within 6 h (ROX-6 score) after HFNO commencement was associated with HFNO success (ROX-6; AHR 0.43, 0.31–0.60), as was use of steroids (AHR 0.35, 95%CI 0.19–0.64). A ROX-6 score of ≥3.7 was 80% predictive of successful weaning whilst ROX-6 ≤ 2.2 was 74% predictive of failure. In total, 139 patents (52%) survived to hospital discharge, whilst mortality amongst HFNO failures with outcomes was 129/140 (92%). In a resource-constrained setting, HFNO for severe COVID-19 HRF is feasible and more almost half of those who receive it can be successfully weaned without the need for mechanical ventilation.